Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2024European Journal of Internal MedicineOpen Access

Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes

View Full Paper
Ask AI
Bookmark
Share

Authors

BJBankole A. JohnsonBristol-Myers Squibb (United States)HAHannu AlhoUniversity of HelsinkiGAGiovanni AddoloratoUniversità Cattolica del Sacro Cuore

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Johnson et al. (2024) studied this question.

synapsesocial.com/papers/68e64b29b6db6435875db9ebhttps://doi.org/10.1016/j.ejim.2024.06.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden2024 · 8 citations
  2. 2Clinical Efficacy of the 5‐HT3 Antagonist Ondansetron in Alcohol Abuse and Dependence1994 · 187 citations
  3. 3High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT 3AB receptor2008 · 81 citations
  4. 4Serotonin Transporter Genomic Biomarker for Quantitative Assessment of Ondansetron Treatment Response in Alcoholics2012 · 15 citations
  5. 5Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study2021 · 20 citations